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Abstract
The DNA enzyme Dz13, targeted against the oncogene c-Jun, is capable of inhibiting various model tumours in mice 
albeit in ectopic models of neoplasia. In previous studies using orthotopic models of disease, the inhibitory effects of 
Dz13 on secondary growth was a direct result of growth inhibition at the primary lesion site. Thus, the direct and 
genuine effects on metastasis were not gauged. In this study, Dz13 was able to inhibit both locoregional and distal 
metastasis of tumour cells in mice, in studies where the primary tumours were unaffected due to the late and clinically-
mimicking nature of treatment commencement. In addition, the effect of Dz13 against tumours has now been 
extended to encompass breast and prostate cancer. Dz13 upregulated the matrix metalloproteinase (MMP)-2 and 
MMP-9, and decreased expression of MT1-MMP (MMP-14) in cultured tumour cells. However, in sections of ectopic 
tumours treated with Dz13, both MMP-2 and MMP-9 were downregulated. Thus, not only is Dz13 able to inhibit 
tumour growth at the primary site, but also able to decrease the ability of neoplastic cells to metastasise. These findings 
further highlight the growing potential of Dz13 as an antineoplastic agent.
Introduction
Dz13 is a DNA enzyme designed originally to reduce inti-
mal thickening in injured rat carotid arteries [1]. Since
then, this particular 'gene shear' molecule has been
shown to have potential therapeutic effects against a vari-
ety of disorders as mentioned below. DNAzymes are syn-
thetic, single-stranded DNA-based catalysts engineered
to bind to their complementary sequence in a target mes-
senger RNA (mRNA) through Watson-Crick rules for
base-pairing and cleave the mRNA at predetermined
phosphodiester linkages (reviewed in [2]). For example,
Dz13 cleaves the target human c-Jun mRNA at position
G1311[1]. By way of a handful of critical studies, these bio-
catalytic molecules have emerged as a potential new class
of nucleic acid-based drugs because of several beneficial
attributes [2].
Dz13 has been shown in ectopic mouse tumour models
to reduce the growth of melanoma indirectly via anti-
angiogenesis [3], while exhibiting direct activity against
squamous cell carcinoma [4], osteosarcoma, OS [5,6] and
liposarcoma [7]. In OS, this agent can be combined with a
frontline drug such as doxorubicin for better efficacy [8],
especially once it has been administered in a nanoencap-
sulated form [9]. While Dz13 has direct anti-tumour
effects based on reduced cell growth and heightened cell
death, the underlying mechanisms have not been eluci-
dated.
The proteolytic breakdown of proteins of the extracel-
lular matrix (ECM) has long been recognized as a hall-
mark of invading primary cancer lesions [10]. Several
classes of proteases contribute to ECM breakdown and
remodeling, most of which are upregulated in the course
of metastatic cancer progression in different types of can-
cers [11]. Matrix metalloproteinases (MMPs) constitute a
family of zinc-dependent endopeptidases that have been
studied in the past few decades in the context of cancer,
and the consensus view at present is that the main role of
MMPs in angiogenesis, tumour growth and metastasis is
degradation of ECM and release and/or activation of
growth factors through such activity. Accordingly, inhibi-
tors to MMPs have entered clinical testing, though the
first clinical trials have led to disappointing results [12].
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One of the critical proteases involved in cell migration
is membrane-type 1 matrix metalloproteinase (MT1-
MMP or MMP-14). MT1-MMP degrades extracellular
matrix to furnish a path for cells to migrate, sheds cell
surface molecules (that can serve as migratory signals),
and activates extracellular signal-regulated protein kinase
(ERK), thus enhancing cell migration [13]. Expression of
MT1-MMP and activation of MMP-2 correlate with pro-
gression in human melanoma [14]. Relative risk of death
in mesothelioma patients with low MT1-MMP expres-
sion is significantly lower than patients with high expres-
sion [15]. However, to date, the role of Dz13 against this
MMP has not been evaluated.
The activation of the 72 kDa type IV collagenase
proMMP-2 (gelatinase A) correlates with increased
occurrence of metastases, and leads to a conversion of the
72 kDa pro-MMP species to a 63 kDa zymogen, mediated
by MT1-MMP activity at the cell surface [16]. In hepatic
stellate cells, involved in liver healing, MT1-MMP acti-
vates MMP-13 which in turn activates MMP-9 [17]. In
non-small-cell lung carcinoma, significant association
with poor survival by both MMP-2 and MMP-9 has been
reported [18]. Expression of MMP-2 and -9 is up-regu-
lated in endometriomas and more pronounced in
advanced stage disease [19]. In gastric cancer, expression
of MMP-2 is strongly associated with tumour progression
and lymph node metastasis [20].
Cleavage of the 92 kDa type IV collagenase proMMP-9
(gelatinase B) results in its activated form, an 82 kDa pro-
tein that has been reported to enhance the invasive phe-
notype of cultured MDA-MB231 cells due to increased
capacity of degradation of ECM and transversing base-
ment membrane following activation [21]. In epithelial
ovarian cancer, overexpression of stromal MMP-9 and
MT1-MMP is independently associated with negative
prognosis [22]. High-grade prostate tumours are more
likely to express MMP-9 [23]. In uroepithelial carcinoma
patients, increased pro-MMP-9 and active MMP-2 levels
correlate with disease progression [24].
Thus, this study demonstrates that Dz13 can downreg-
ulate MMP-2, MMP-9 and MMP-14 levels in tumour
cells, in addition to downregulating its target gene c-Jun,
with no effect on the AP-1 transcription factor compo-
nent (and associate of c-Jun), c-Fos. Moreover, this study
seminally demonstrates the direct antimetastatic ability
of Dz13 in models of tumour progression.
Materials and methods
Cells
The human prostate cancer PC3, breast cancer MDA-
MB231, osteosarcoma SaOS-2, and osteosarcoma 143B
cell lines were from the ATCC (Virginia, USA), while the
osteosarcoma G292 cell line was from D. Thomas (Peter
MacCallum Cancer Institute, Melbourne, Australia).
Cells were propagated in α-MEM supplemented with
10% FBS and 1% antibiotic-antimycotic (complete
medium). Cell lines were maintained up to 20 passages in
a 37°C/5% CO2 incubator, and were ensured to be >95%
viable.
DNAzyme transfection
The 34 mer, 10-23 class of deoxyribozymes, Dz13 and Scr
(the scrambled sequence control for Dz13) oligonucle-
otides were synthesised and prepared according to estab-
lished conditions [25]. DNAzyme (0.8 μM) was
transfected with Fugene-6 liposomes (Roche Diagnostics,
Sydney, Australia) in complete medium.
Western blotting
Treated cell lysates were immunoblotted as per a pub-
lished method [26]. Briefly, post-transfection, cells were
gently lysed with RIPA (150 mM NaCl, 50 mM Tris, 1
mM EDTA, 0.1% SDS, 1% Triton X-100 pH 7.4) buffer
containing complete protease inhibitors (Roche Diagnos-
tics). All primary antibodies were from Santa Cruz Bio-
technology (Santa Cruz, CA, USA), and all horseradish
peroxidise (HRP)-conjugated secondary antibodies were
from Dako.
Immunohistochemistry (IHC)
IHC was performed as before [27] on paraformaldehyde-
fixed paraffin-embedded tumour specimens. 5 μm sec-
tions were deparaffinised in xylene, then rehydrated in a
graded ethanol series. High pH (9.5) 10 mM Tris/1 mM
EDTA buffer at 95°C was used for antigen retrieval. All
primary antibodies were from Santa Cruz Biotechnology
and were incubated overnight at 4°C. Secondary biotiny-
lated antibodies (Dako, Sydney, Australia) were incubated
with specimens at room temperature for 1 h.
Establishment of metastasising 143B tumour model
Prior approval for all animal experimentation was
obtained from the St. Vincent's Health Animal Ethics
Committee. Female 5-week-old Balb/c nude mice (n = 3,
sourced from the Animal Resources Centre, Perth, Aus-
tralia) were anaesthetised with ketamine (100 mg/kg) and
xylazine (10 mg/kg). 2.5 × 105 143B tumor cells in 50%
Matrigel (BD Biosciences, Sydney, Australia) were
injected into the inguinal fatpad of 5-week-old female
Balb/c nude mice. At the end of the study, the peritoneal
cavity was checked for local metastases and the liver and
lungs for distal metastases, photographs were taken, and
tissues were processed histologically.
Proof of anti-metastatic activity of Dz13 against novel 143B 
tumour model
As above, 143B tumor cells in 50% Matrigel were injected
into the inguinal fatpad of mice. Dz13 or Scr (250 ng) in
saline was administered intraperitoneally 6 weeks laterTan et al. Cancer Cell International 2010, 10:9
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when tumours became palpable. Four weeks later, pri-
mary tumours were weighed, and local and lung macro-
metastases were counted. The peritoneal cavity was
checked for local metastases and the lungs for distal
metastases, and tumours processed histologically.
Test of Dz13 against metastasis of cancer cells from an 
orthotopic tumour
Female 5-week-old Balb/c nude mice (n = 4 per group)
were anaesthetised with ketamine (100 mg/kg) and xyla-
zine (10 mg/kg). 2 × 104 SaOS-2 tumour cells in 50%
Matrigel was injected intratibially in a volume of 20 μL in
the proximal tibia using a 26G needle and a gentle 'screw-
ing' motion to prevent bone cortex rupture a before [28].
The general condition of all mice were observed before
the tumours were measured apically (AP) and longitudi-
nally (L) with digital callipers. Taking into consideration
tumour bulge, AP was measured left-to-right across the
knee-cap and L was an anterior-to-posterior measure-
ment of the tibia (all measurements obtained where the
tumour growth was maximal). Tibial tumour volume was
calculated using the formula: 4/3π [0.25(AP+L)]2 [29]. A
lung lobe of 3 representative mice from each treatment
group was processed histologically [30] and sectioned at
5 μm at every 100 μm interval. The number of microme-
tastases in each section was then counted for each cohort
and summed.
Proof-of-principle Dz13 activity studies against ectopic 
tumors
Prior approval for use of mice was obtained from the St.
Vincent's Health Animal Ethics Committee. Female 5-
week-old Balb/c nude mice (n = 5 per group) were anaes-
thetised with ketamine (100 mg/kg) and xylazine (10 mg/
kg). Dz13 was mixed with PC3, MDA-MB231 or SJSA-1
tumour cells (1 × 106) at a concentration of 0.4 μM in 50%
Matrigel (BD Biosciences) prior to ectopic injection sub-
cutaneously in the midback of 5 week-old Balb/C nu/nu
mice. Backflow of the injectate was prevented by retract-
ing the needle post-injection slowly from the injection
site. Mice were fed and hydrated ad libitum and moni-
tored twice weekly for tumour development, and then
three times weekly when tumours were palpable. Tumour
volumes were measured and tumours histologically pro-
cessed as per published method [31,32].
Statistical analysis
All data were analysed using the one-way student's t-test
with unequal variances.
Results
Locally and distally metastasising osteosarcoma model
In this study, when 143B cells were injected into the fat-
pad, palpable tumours arose at 3 weeks post-injection
(Fig. 1a). At this early stage, tumours were almost white in
colour with a maximal dimension of 5 mm across (Fig.
1b). Clearly discernible tumours appeared around 4
weeks (Fig. 1c). At the 6-week stage, tumours were
approximately 1 cm × 1 cm in length and width dimen-
sions, with a healthy pink hue and easily delineated ves-
sels indicating aggressive tumour growth (Fig. 1d). At this
point, several macrometastases were noted in the visceral
walls surrounding peritoneal organs, including the intes-
tines (Fig. 1e). Some of these locoregional growths were
at least 1 cm away from the parent tumour (Fig. 1f). Evi-
dence of macrometastases was noted on the surface of
lungs, though these were almost pin-point size. Confir-
mation with histology revealed that 143B cells did travel
to and establish in the lungs from the peritoneum (Fig.
1g).
Dz13 directly inhibits local as well as distal tumour 
metastasis
The novel 143B model was then applied to directly test
the effects of Dz13 against metastasis. Dz13 was adminis-
tered 6 weeks after 143B cells were injected to ensure that
primary tumours were unaffected (Fig. 2a) but an effect
on metastasis could nevertheless be monitored. To this
end, both local metastases in the peritoneal cavity and
walls (Fig. 2b) and distal metastases to the lungs (Fig. 2c)
were reduced. Thus, efficacy of Dz13 against metastasis
was readily observed. The Scr control did not affect either
primary tumour or metastasis. In addition, effects of
Dz13 were tested on OS metastasis from the bone, this
time with the established SaOS-2 tumour model [28].
Tumours were allowed to grow to around 1 cm in both
the AP and L dimensions, before Dz13 was administered
Figure 1 Characterisation of the 143B locally metastasising mod-
el. This model can be used for testing of the antimetastatic properties 
of candidate therapeutic agents against osteosarcoma. 143B cells were 
injected into the inguinal fatpad of mice. A, palpable tumour at 2 
weeks post-injection, B, exposed tumour at 2 weeks post-injection, C, 
clearly discernible tumour at 4 weeks, D, exposed tumour at 4 weeks, 
E, white arrowhead indicates site of primary tumour, black arrowhead 
indicates site of secondary locoregional tumour, F, arrowhead, site of 
locoregional tumour metastasis, G, arrowhead, pulmonary metastasis 
within lung parenchyma. Scale bar = 25 μm.Tan et al. Cancer Cell International 2010, 10:9
http://www.cancerci.com/content/10/1/9
Page 4 of 8
intravenously in bolus dosages. Lung surface macrome-
tastases were reduced in the Dz13 cohort of mice (Fig.
3a), and so were lung micrometastases (Fig. 3b). Histolog-
ical examination of lung lobe sections revealed that both
size and number of micrometastases were reduced when
animals were administered Dz13, but not Scr oligonucle-
otide (Fig. 3c). Tumour measurements at the tibiae of
mice shows equal mean lesion volumes across the treat-
ment groups (Fig. 3d).
Dz13 alters matrix metalloproteinase levels in tumour cells
Having demonstrated that Dz13 can directly inhibit
tumour metastasis, the underlying molecular mecha-
nisms were examined. Since MMP-2 and MMP-9 have
been associated with c-Jun regulation [3,4], these agents
of ECM breakdown were explored. In addition, MT1-
MMP (MMP-14) was also evaluated. Lysates for Dz13-
and Scr-treated human osteosarcoma SJSA-1 cells were
immunoblotted. Levels of activated MMP-2 increased
initially, but then decreased after 1 h post-transfection
with Dz13 (Fig. 4). Interestingly, MMP-9 was activated as
time progressed post-transfection of cells with Dz13.
However, for MT1-MMP, levels consistently decreased as
the assay progressed.
Dz13 reduces ectopic osteosarcoma, prostate and breast 
tumour growths
Ectopic osteosarcoma (G292), prostate (PC3) and breast
(MDA-MB231) tumour growths were reduced by Dz13
(Fig. 5). A statistical difference in tumour volume was
noted at day 32 post-injection of cells, and at the end of
the study (day 35), Dz13-treated tumour growths were
clearly stunted. Less aggressive growth was noted with
Figure 2 Dz13 inhibits 143B tumour metastasis. Dz13 was tested in 
the novel intraperitoneal 143B model. (A) Primary tumours were unaf-
fected. (B) Dz13 inhibits tumour metastasis locally in the peritoneum. 
(C) Dz13 inhibits tumour metastases to a distal site (lung). n = 5, error 
bars represent standard deviations.
Figure 3 Dz13 inhibits OS metastasis from the bone efficaciously. 
Dz13 efficacy was next tested in the SaOS-2 orthotopic model. Dz13 
was able to reduce OS metastasis to the lung after treatment was ad-
ministered when tumours were palpable. Both macrometastasis (A) 
and micrometastasis (B) counts were reduced in the Dz13 cohort. (C) 
Histology confirmed that there were less micrometastases in lungs of 
mice in the Dz13 cohort (middle) compared to untreated (top) and Scr-
treated (bottom). (D) Primary tumour was not affected by the treat-
ments administered.
Figure 4 Dz13 downregulated matrix metalloproteinases in tu-
mour cells. Two osteosarcoma cell lines were transfected with Dz13 
and cell lysates harvested at the indicated time-points. Lysates were 
immunoblotted for the MMP-2, -9 and -14 (MT1-MMP). GAPDH indi-
cates equivalent loading between samples.Tan et al. Cancer Cell International 2010, 10:9
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Dz13 treatment as manifested by sparse growth of
tumour cells within the lesion (Fig. 6), which in itself was
small and close to the underlying muscle. The Scr control
tumours were the same volumes as the untreated
tumours.
Dz13 downregulates target c-Jun and MMP levels in 
ectopic tumours
Ectopic osteosarcoma (G292), prostate (PC3) and breast
(MDA-MB231) tumour sections were evaluated by
immunohistochemistry for c-Jun and c-Fos (off-target
control). c-Jun levels were decreased in all tumours, but
c-Fos was not (Fig. 7). Likewise, MMP-2 levels were
slightly lower in Dz13-treated tumours (Fig. 8). Immuno-
histochemistry for MMP-9 revealed a clear downregula-
tion of this MMP as a result of Dz13 treatment of
tumours (Fig. 9). Akin to results in vitro, levels of MT1-
MMP were reduced in all tumours in vivo (Fig. 10).
Discussion
In the future, Dz13 may be a feasible approach to tumour
management. Metastasis is the event in tumorigenesis
that signals advanced stage disease, and one that is unfor-
tunately frequently not amenable to medical intervention.
As such, agents capable of reducing the impact of metas-
tasis are likely to significantly alter the current manage-
ment strategies for cancers. This is surely the case for OS
Figure 6 Dz13 reduces aggressiveness of ectopic osteosarcoma, 
prostate and breast tumour growths. Haematoxylin- and eosin-
stained osteosarcoma (G292), prostate (PC3) and breast (MDA-MB231) 
tumour sections are shown. In the Dz13 cohorts, less aggressive tu-
mour growth is noted as sparse cell density and smaller area of occu-
pation. Arrowheads: black, areas of dense cell growth, white, areas of 
sparse cell growth. Scr, scrambled sequence oligonucleotide of Dz13. 
Scale bar = 25 μm. Representative images are shown. Scale bar = 25 μm, 
n = 5.
Figure 7 Dz13 downregulates target c-Jun levels in ectopic oste-
osarcoma, prostate and breast tumours. Ectopic osteosarcoma 
(G292), prostate (PC3) and breast (MDA-MB231) tumour sections were 
evaluated by immunohistochemistry for c-Jun and c-Fos (off-target 
control). c-Jun and c-Fos (inserts)-immunostained tumour sections are 
shown. Representative images are shown. Negative control sections 
(no primary antibody) ruled out non-specific staining. Scale bar = 25 
μm, n = 5.
Figure 5 Dz13 reduces volume of ectopic (subcutaneous) osteo-
sarcoma, prostate and breast tumour growths. Ectopic osteosarco-
ma (G292), prostate (PC3) and breast (MDA-MB231) tumour growths 
were reduced by Dz13. Real-time tumour growth graphs are present-
ed. Inserts show photographs of harvested representative tumours 
from the cohorts for each cell line. n = 5, error bars represent standard 
deviations.Tan et al. Cancer Cell International 2010, 10:9
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[33], where with good management strategies, the 10-
year disease-free survival is about 60% in patients with
localised disease and 30% in patients with metastatic dis-
ease at diagnosis.
c-Jun, in the form of the AP-I complex, regulates MMP-
9 levels in mammalian cells [34]. This oncoprotein is also
known to regulate expression of MMP-2 [35,36]. In fact,
in OS cells, c-Jun has been linked to both MMP-2 and
MMP-9 activities and to cell ability to invade [37]. c-Jun
also regulates MT1-MMP levels in mammalian cells [38].
As mentioned above, it has been previously demon-
strated that Dz13, which downregulates c-Jun, can in fact
regulate MMP-2 expression and subsequent activity in
endothelial cells [3] and MMP-2 and -9 in squamous cell
carcinoma cells [4].
Thus, here we extend Dz13 action on MMPs, specifi-
cally showing that MT1-MMP is downregulated when
OS cells are treated with Dz13, a novel finding since
MT1-MMP was not evaluated in previous Dz13 studies
[3,4]. However, in discordance with previous findings,
our studies show that Dz13 firstly upregulates MMP-2 in
cultured OS cells, and levels decrease to baseline (unde-
tectable) at later time-points. In addition, another variant
from previous findings was the increasing MMP-9 activa-
tion in cells treated with Dz13 as time progressed. One
explanation is that these findings could be due to the link
that both MMP-2 and MMP-9 have with apoptosis [39],
which is known to commonly occur with Dz13 treatment
of tumour cells [40].
This study is also novel in that it seminally proved the
d i r e c t  e f f e c t  o f  D z 1 3  o n  t u m o u r  m e t a s t a s i s .  T o  t e s t
whether Dz13 can directly inhibit tumour metastasis,
rather than as a result of primary tumour inhibition as
demonstrated before [5-8], a locally metastasising model
was established. 143B cells were injected into the inguinal
fatpad of mice, at a region which facilitates easy manipu-
lation of the mice (drug administration and hence testing
without anaesthesia of animals, site at which animal can-
not physically affect tumour growth with limbs or snout,
tumour measurements can be obtained without need for
animal immobilisation, and cells are secured in a speci-
fied spot within fatpad and not floating around in perito-
neum). OS does in fact metastasise to the peritoneum in
patients, albeit from organs other than bone [41,42]. One
advantage of this model over other OS models using
Figure 8 Dz13 downregulates MMP-2 in ectopic osteosarcoma, 
prostate and breast tumours. Ectopic osteosarcoma (G292), prostate 
(PC3) and breast (MDA-MB231) tumour sections were evaluated by im-
munohistochemistry for MMP-2. Representative images are shown. 
Negative control sections (no primary antibody) ruled out non-specific 
staining. Scale bar = 25 μm, n = 5.
Figure 9 Dz13 downregulates MMP-9 in ectopic osteosarcoma, 
prostate and breast tumours. Ectopic osteosarcoma (G292), prostate 
(PC3) and breast (MDA-MB231) tumour sections were evaluated by im-
munohistochemistry for MMP-9. Representative images are shown. 
Negative control sections (no primary antibody) ruled out non-specific 
staining. Scale bar = 25 μm, n = 5.
Figure 10 Dz13 downregulates MT1-MMP in ectopic osteosarco-
ma, prostate and breast tumours. Ectopic osteosarcoma (G292), 
prostate (PC3) and breast (MDA-MB231) tumour sections were evalu-
ated by immunohistochemistry for MT1-MMP. Representative images 
are shown. Negative control sections (no primary antibody) ruled out 
non-specific staining. Scale bar = 12.5 μm, n = 5.Tan et al. Cancer Cell International 2010, 10:9
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human cells [28,43] is the presence of both regional and
d i s t a l  m e t a s t a s e s  i n  t h e  p e r i t o n e u m  a n d  s u r r o u n d i n g
walls and the lungs respectively. This model can be used
for testing of the antimetastatic properties of candidate
therapeutic agents against OS due to the aforementioned
advantages.
In both the 143B fatpad model and in an orthotopic
model for OS, where cells are injected directly into bone
[28], primary tumours were left to grow until a stage
where treatment would have no effect on the primary
lesion. When Dz13 was then used, the development of
metastases was significantly inhibited in both models.
The Scr control oligonucleotide had no effect on
tumours.
While MMPs levels were perturbed in cultured cells,
the effects of Dz13 in vivo needed to be tested in a panel
of tumour types. The tumours evaluated consisted of
prostate, breast and osteosarcoma, though ectopic mod-
els were used to examine protein levels via tumour sec-
tion immunohistochemistry (IHC). When IHC was
performed, a consistent decrease in MMP-2 and MMP-9
levels was noted in the Dz13 cohort of animals compared
to both the saline-treated and Scr-treated tumours. Thus,
while in vitro results suggest that MMP levels may fluctu-
ate and even increase via activation, in vivo results
showed a consistent decrease in MMPs by Dz13. The dis-
crepancy could be due to the fact that in culture, cells
were exposed to a very potent Dz13 onslaught in a 2-D
configuration, while in vivo, cells were protected by the
Matrigel and the 3-D nature of the injected 'colony' of
cells, and treatment was protracted over 5 weeks. How-
ever, what was consistent was the finding that both in
vitro and in vivo, levels of MT1-MMP were reduced in
tumour cells treated with Dz13 but not the scrambled
control.
In addition, in vivo, significant decrease in c-Jun levels
were noted for all ectopic tumours treated with Dz13 but
not when cells were treated with the Scr control oligonu-
cleotide. In vitro, cells have to be serum-starved prior to
growth induction (and c-Jun elevation) before Dz13
shows it effects [1,3,4], but in vivo, where such a protocol
is irrelevant, except in areas of the tumour where new
blood supply has been established after a certain degree
of ischaemia, Dz13 is active against its target mRNA, the
c-Jun oncogene. No changes in c-Fos levels were noted.
Thus, for DNAzyme technology in general, the need for
serum-starvation in culture [31,32], while providing criti-
cal proof that the catalytic nucleic acid is active against its
target, may fail to be indicative of what occurs in vivo,
and in fact is an underestimation of the potent action of
Dz13 against its target.
For Dz13, the present set of results further highlight the
inherent potential of this molecule. Not only is it able to
control tumour at the primary site, but also at the second-
ary site as well. As for other tumours, and particularly in
OS, while the primary tumour may be removed in a good
number of cases, it is the metastases which become life-
threatening [44]. Further studies with other metastasising
tumours may prove the widespread beneficial effects of
Dz13.
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